Sartorius Stedim Biotech S.A. updated earnings guidance for the year 2022. The company's outlook for fiscal 2022, updated on February 8, was also confirmed. Accordingly, Group sales revenue is expected to increase by about 15% to 19%.

This includes an expected non-organic growth contribution from acquisitions of about 2% points. The company's underlying EBITDA margin is forecasted to reach more than 35%.